Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 6.55 -0.29 (4.24%)
Day High: 6.85
Day Low:  6.51
Volume:    1,060,780
4:00 PM ET
Sep 22, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations